GU Cancers 2020 | EV-101: enfortumab vedotin for UC

VJOncology is committed to improving our service to you

Daniel Petrylak

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses results from the recent EV-101 study (NCT02091999), assessing the use of enfortumab vedotin in patients with metastatic urothelial carcinoma (UC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter